CoChat

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index; 9 of the 35 sources its claims cite were checked for support.

Corepressor-dependent silencing of fetal hemoglobin expression by BCL11A

Open access

Abstract

Reactivation of fetal hemoglobin (HbF) in adults ameliorates the severity of the common β-globin disorders. The transcription factor BCL11A is a critical modulator of hemoglobin switching and HbF silencing, yet the molecular mechanism through which BCL11A coordinates the developmental switch is incompletely understood. Particularly, the identities of BCL11A cooperating protein complexes and their roles in HbF expression and erythroid development remain largely unknown. Here we determine the interacting partner proteins of BCL11A in erythroid cells by a proteomic screen. BCL11A is found within multiprotein complexes consisting of erythroid transcription factors, transcriptional corepressors, and chromatin-modifying enzymes. We show that the lysine-specific demethylase 1 and repressor element-1 silencing transcription factor corepressor 1 (LSD1/CoREST) histone demethylase complex interacts with BCL11A and is required for full developmental silencing of mouse embryonic β-like globin genes and human γ-globin genes in adult erythroid cells in vivo. In addition, LSD1 is essential for normal erythroid development. Furthermore, the DNA methyltransferase 1 (DNMT1) is identified as a BCL11A-associated protein in the proteomic screen. DNMT1 is required to maintain HbF silencing in primary human adult erythroid cells. DNMT1 haploinsufficiency combined with BCL11A deficiency further enhances γ-globin expression in adult animals. Our findings provide important insights into the mechanistic roles of BCL11A in HbF silencing and clues for therapeutic targeting of BCL11A in β-hemoglobinopathies.

Overview

CoChat Summary

TL;DR

BCL11A silences fetal hemoglobin by assembling multiprotein corepressor complexes in erythroid cells, including LSD1/CoREST, NuRD, and DNMT1. Genetic and RNAi experiments show these partners contribute to γ-globin/embryonic β-like globin silencing, but LSD1 and DNMT1 also have broader roles that limit their therapeutic targeting.

Key findings

  • A proteomic affinity screen in MEL and K562 erythroid cells identified BCL11A-interacting proteins including the LSD1/CoREST histone demethylase complex, NuRD complex, SIN3, NCoR/SMRT, BCOR, DNMT1, and SWI/SNF; interactions were confirmed by co-IP in primary human erythroid cells.
  • In primary human CD34+ HSPC-derived erythroid cells, shRNA knockdown of BCL11A-interacting corepressors increased γ-globin; top-ranked genes included NuRD subunits (CHD4, HDAC1, HDAC2, MBD2), DNMT1, SIN3A, NCOR1, and PRC2 subunits (EZH2, EED, SUZ12). Depletion of KLF1, but not BCL11A, significantly increased ε-globin.
  • LSD1/CoREST loss derepressed mouse embryonic β-like globins: E12.5 Lsd1 KO increased εy- and βh1-globin 6.2- and 26.7-fold; E13.5 CoREST KO increased them 13.0- and 15.4-fold; adult Mx1-Cre LSD1 cKO increased them 5.8- and 10.6-fold. BCL11A deletion caused much greater increases (31.2- to 232.9-fold).
  • Compound BCL11A/LSD1 loss further enhanced γ-globin: Bcl11a−/−::Lsd1+/− mice had 13.53% γ-globin versus 8.40% in Bcl11a−/− mice (P = 0.0006); Bcl11a−/−::Lsd1−/− mice had 18.19% versus 12.88% with BCL11A loss alone (P = 0.03). DNMT1 haploinsufficiency plus BCL11A deficiency increased γ-globin from 11.16% to 23.58% (2.1-fold, P = 1.9 × 10−6).

Methods

  • Proteomic screen: stable MEL and K562 lines expressing BirA alone or FLAG-BirA-tagged BCL11A XL isoform; streptavidin and/or anti-FLAG affinity purification followed by LC-MS/MS, with co-IP validation in erythroid cells.
  • Functional RNAi screen: lentiviral shRNAs targeting BCL11A or interacting proteins in primary adult human CD34+ HSPCs undergoing ex vivo erythroid maturation; qRT-PCR for globin expression, with shRNAs achieving >75% target mRNA knockdown selected.
  • Chromatin and mouse genetics: ChIP-qPCR in primary human adult erythroid cells with control or BCL11A knockdown; conditional floxed Lsd1, Rcor1, Bcl11a, and Dnmt1 alleles crossed with EpoR-Cre or Mx1-Cre, including β-YAC transgenic mice, analyzed by qRT-PCR and hematology.

Limitations

  • Stated: primary human erythroid cultures have higher background γ-globin than normal adult erythroid cells and CD34+ HSPCs are permissive for HbF induction, making them sensitive but not necessarily specific; growth kinetics and differentiation status affect HbF. β-YAC mice have far lower baseline transgenic γ-globin than normal individuals, so interventions face a greater quantitative hurdle, and effects are small compared with BCL11A KO.
  • Stated: LSD1 and DNMT1 have broad roles in hematopoiesis; LSD1 KO is embryonic lethal with severe anemia, and complete DNMT1 loss is incompatible with normal hematopoietic development, suggesting a narrow therapeutic window.
  • Evident from the text: RNAi effects may reflect incomplete knockdown, and compound KO experiments used heterozygous Lsd1 or Dnmt1 in some settings because homozygous loss causes lethality, so full loss-of-function contributions were not always tested.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1073/pnas.1303976110

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Image 1
From the PDF
Fig. 2 Functional RNAi screen of BCL11A-interacting proteins in primary human erythroid cells. ( A ) Schematic diagram of experimental design. ( B ) Expression of human γ -globin mRNA was measured by qRT-PCR. Data are plotted as percentage of γ -globin over total β -like human globin gene levels (two to fi ve shRNAs per gene). Genes are ranked based on the level of γ -globin expression (highest to lowest). ( C ) Genes are ranked based on the level of e -globin expression (highest to lowest). ( D ) Expression of human total β -like globin mRNA normalized to GAPDH mRNA level. Results are the means ± SD of at least three independent experiments.
Fig. 2 Functional RNAi screen of BCL11A-interacting proteins in primary human erythroid cells. ( A ) Schematic diagram of experimental design. ( B ) Expression of human γ -globin mRNA was measured by qRT-PCR. Data are plotted as percentage of γ -globin over total β -like human globin gene levels (two to fi ve shRNAs per gene). Genes are ranked based on the level of γ -globin expression (highest to lowest). ( C ) Genes are ranked based on the level of e -globin expression (highest to lowest). ( D ) Expression of human total β -like globin mRNA normalized to GAPDH mRNA level. Results are the means ± SD of at least three independent experiments.From the PDF
Image 3
From the PDF
Fig. 4 The LSD1/CoREST complex is required for silencing of mouse embryonic β -like globin genes. ( A ) Expression of mouse embryonic ( e y and β h1) globin genes was monitored by qRT-PCR in E12.5 fetal livers of control ( Lsd1 + / + ) and LSD1 KO ( Lsd1 -/ -; by EpoR-Cre) embryos. All data are shown as percentage (%) of total mouse β -like globin expression. The fold changes of globin mRNAs are indicated. Results are means ± SD ( n ≥ 5 per genotype; P < 0.05). ( B ) Expression of e y- and β h1-globin genes in E13.5 fetal livers of control and CoREST KO ( Rcor1 -/ -) embryos ( n ≥ 3 per genotype; P < 0.05). ( C ) Expression of e y- and β h1-globin genes in E12.5 fetal livers of control and BCL11A KO ( Bcl11a -/ -; by EpoR-Cre) embryos ( n ≥ 3 per genotype; P < 0.01). ( D ) Expression of e y- and β h1globin genes in PB of control and LSD1;Mx1-Cre cKO mice (3 wk post-pIpC, 9 -15 wk old; n ≥ 5 per genotype; P < 0.05). ( E ) Expression of e y- and β h1-globin genes in PB of control and BCL11A;Mx1-Cre cKO mice (3 wk post-pIpC, 9 -15 wk old; n ≥ 3 per genotype; P < 0.01).
Fig. 4 The LSD1/CoREST complex is required for silencing of mouse embryonic β -like globin genes. ( A ) Expression of mouse embryonic ( e y and β h1) globin genes was monitored by qRT-PCR in E12.5 fetal livers of control ( Lsd1 + / + ) and LSD1 KO ( Lsd1 -/ -; by EpoR-Cre) embryos. All data are shown as percentage (%) of total mouse β -like globin expression. The fold changes of globin mRNAs are indicated. Results are means ± SD ( n ≥ 5 per genotype; P < 0.05). ( B ) Expression of e y- and β h1-globin genes in E13.5 fetal livers of control and CoREST KO ( Rcor1 -/ -) embryos ( n ≥ 3 per genotype; P < 0.05). ( C ) Expression of e y- and β h1-globin genes in E12.5 fetal livers of control and BCL11A KO ( Bcl11a -/ -; by EpoR-Cre) embryos ( n ≥ 3 per genotype; P < 0.01). ( D ) Expression of e y- and β h1globin genes in PB of control and LSD1;Mx1-Cre cKO mice (3 wk post-pIpC, 9 -15 wk old; n ≥ 5 per genotype; P < 0.05). ( E ) Expression of e y- and β h1-globin genes in PB of control and BCL11A;Mx1-Cre cKO mice (3 wk post-pIpC, 9 -15 wk old; n ≥ 3 per genotype; P < 0.01).From the PDF
Fig. 5 Compound KO of Bcl11a , Lsd1 , or Dnmt1 enhances γ -globin expression. ( A ) Expression of γ -globin mRNA was measured by qRT-PCR in peripheral blood (PB) of Bcl11a::Lsd1 cKO animals (by EpoR-Cre; 8 -12 wk old). Results are the means ± SD. P values were determined by a two-tailed t test. ( B ) Expression of γ -globin in PB of Bcl11a::Lsd1 cKO animals (by Mx1-Cre; 8 -12 wk old). ( C ) Lentiviral shRNA-mediated knockdown of BCL11A and LSD1 proteins in primary human erythroid cells. ( D ) Knockdown of BCL11A or LSD1 results in increased γ -globin mRNAs ( Upper ). Knockdown of LSD1 reduces total β -like globin mRNAs ( Lower ). Data are shown as means ± SD; * P < 0.05, ** P < 0.01. ( E ) shRNA-mediated knockdown of DNMT1 in primary human erythroid cells ( Upper ) results in increase of γ -globin mRNAs and modest decrease in total β -like globin mRNAs ( Lower ). Data are shown as means ± SD; * P < 0.05. ( F ) Expression of γ -globin in PB of Dnmt1::Bcl11a cKO animals (by EpoR-Cre; 8 -12 wk old).
Fig. 5 Compound KO of Bcl11a , Lsd1 , or Dnmt1 enhances γ -globin expression. ( A ) Expression of γ -globin mRNA was measured by qRT-PCR in peripheral blood (PB) of Bcl11a::Lsd1 cKO animals (by EpoR-Cre; 8 -12 wk old). Results are the means ± SD. P values were determined by a two-tailed t test. ( B ) Expression of γ -globin in PB of Bcl11a::Lsd1 cKO animals (by Mx1-Cre; 8 -12 wk old). ( C ) Lentiviral shRNA-mediated knockdown of BCL11A and LSD1 proteins in primary human erythroid cells. ( D ) Knockdown of BCL11A or LSD1 results in increased γ -globin mRNAs ( Upper ). Knockdown of LSD1 reduces total β -like globin mRNAs ( Lower ). Data are shown as means ± SD; * P < 0.05, ** P < 0.01. ( E ) shRNA-mediated knockdown of DNMT1 in primary human erythroid cells ( Upper ) results in increase of γ -globin mRNAs and modest decrease in total β -like globin mRNAs ( Lower ). Data are shown as means ± SD; * P < 0.05. ( F ) Expression of γ -globin in PB of Dnmt1::Bcl11a cKO animals (by EpoR-Cre; 8 -12 wk old).From the PDF

Verification

Claims the paper makes

8 Valid · 1 Not valid · 15 Not checked · 97 Own results and interpretations

88 more claims

Create a free account to see all 121 claims and to verify the 1 reference still open.

See all claims — free account
  • It may state two separate claims as one. 19
  • Probably not a substantial claim. 11

Create a free account to see these claims.

Citations

Cites

Show all 29 references

Cited by

See all 233

Metadata

Authors
Xu, J., Bauer, D. E., Kerenyi, M. A., Vo, T. D., Hou, S., Hsu, Y.-J., Yao, H., Trowbridge, J. J., Mandel, G., & Orkin, S. H.
Affiliations
  • Boston Children's Hospital (US)
  • Howard Hughes Medical Institute (US)
Corresponding author
Orkin, Stuart H.
Venue
Proceedings of the National Academy of Sciences
Published
2013-04
Volume
110
Issue
16
Pages
6518-6523
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2161143576
Cited by
233
References
29
Citations by year
2026: 11 · 2025: 13 · 2024: 17 · 2023: 16 · 2022: 15 · 2021: 30 · 2020: 20 · 2019: 12 · 2018: 19 · 2017: 20 · 2016: 24 · 2015: 16 · 2014: 12 · 2013: 8
FWCI
9.84
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • The Mouseion at the JAXlibrary (Jackson Laboratory) (submittedVersion)
Funders
  • Howard Hughes Medical Institute
  • National Institutes of Health
  • National Heart, Lung, and Blood Institute (R01HL032259)
  • National Institute of Diabetes and Digestive and Kidney Diseases (P30DK049216, K01DK093543, P30DK056465, K08DK093705)
Topics
  • Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Hemoglobin structure and function
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
Keywords
BCL11A, hemoglobin switching, erythroid development, histone demethylation, DNMT1, DNA methylation, corepressors, beta-globin gene, γ-globin expression, β-hemoglobinopathies, protein-protein interaction
MeSH terms
Animals, Carrier Proteins, Chromatin, Chromatography, Liquid, Fetal Hemoglobin, Humans, Nuclear Proteins, Repressor Proteins, Erythroid Precursor Cells, Gene Expression Regulation, Developmental, RNA Interference, Proteomics, Cell Line, Tumor, Multiprotein Complexes, Chromatin Immunoprecipitation, Mice, Tandem Mass Spectrometry, beta-Globins, Co-Repressor Proteins, Real-Time Polymerase Chain Reaction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Corepressor-dependent silencing of fetal hemoglobin expression by BCL11A. https://app.cochat.ai/papers/10.1073/pnas.1303976110
The paper
Xu, J., Bauer, D. E., Kerenyi, M. A., Vo, T. D., Hou, S., Hsu, Y.-J., Yao, H., Trowbridge, J. J., Mandel, G., & Orkin, S. H. (2013). Corepressor-dependent silencing of fetal hemoglobin expression by BCL11A. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1303976110

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.